Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

Immune checkpoint inhibitors can increase the risk of autoimmune skin diseases, especially bullous pemphigoid.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Cancer treatments targeting specific cells often cause skin problems, which can affect how much medicine patients can take.

Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.

Anti-CD19 therapy may help treat SLE and NMOSD.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Aging and chronic inflammation weaken the immune system, increasing cancer and infection risks.

Tridax procumbens may boost the immune system.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Age-related immune changes significantly affect disease development in other systems.

Immunological treatment improved both neuropathy and alopecia.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

FK506 may stimulate hair growth when applied to the skin.